Myeloproliferative Neoplasms
The latest news, research, and perspectives in myeloproliferative neoplasms (MPNs). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.
Advertisement
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Investigators observed that overall treatment has improved but hospitalizations and other events indicate unaddressed need.
Harboring high molecular risk mutations and a lower JAK2V617F VAF were independent adverse prognostic factors for survival.
The Myelofibrosis Symptom Assessment Form is the only instrument currently available for evaluating myelofibrosis symptoms.
According to John O. Mascarenhas, MD, the phase 3 MANIFEST study heralds a new era of combination therapy for myelofibrosis.
In a phase 2 trial the hepcidin mimetic increased hematocrit control while reducing phlebotomy and patient-reported symptoms.
Advertisement
Most patients with JAK2, CALR, and MPL mutations had mutation clearance 100 days after HSCT.
A study found limits to the prediction utility of thrombosis history in patients with PV and pulmonary hypertension risk.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Andrew Kuykendall, MD, presented on the status of myelofibrosis treatment in the era of 4 approved JAK inhibitors.
MRD testing before HSCT may offer insight into survival outcomes for patients with MDS/MPN.
Discussing the evolving role of selinexor in treatment of myeloproliferative neoplasms.
Watch as Viges and Dr. Mascarenhas explore strategies to enhance patient-centered care in MPN management.
Exploring the latest advancements in myelofibrosis research with Kapila Viges, MD and John Mascarenhas, MD.
Two experts discuss the role of surrogate end points in MPN clinical trials.
A new study has identified genetic factors that can affect the molecular pathways involved in treatment response.
A common treatment goal for polcythemia vera is to control HCT with therapy, phlebotomies, and cytoreductive therapies.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
VGT-1849A is aJAK2 inhibitor that is designed to have less off-target suppression of JAK1, JAK3, TYK2, and other kinases.
SURPASS-ET compared second-line treatment with ropeginterferon alfa-2b with anagrelide in patients with ET.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.